Trials / Recruiting
RecruitingNCT07137689
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
Pharmacokinetics of LY3537982 Following a Single Dose in Participants With Renal Impairment Compared With Participants With Normal Renal Function
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3537982 | Administered orally |
Timeline
- Start date
- 2025-08-18
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2025-08-22
- Last updated
- 2026-03-12
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07137689. Inclusion in this directory is not an endorsement.